• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Exits

VC-backed Biocartis lists with €450m market cap

  • Greg Gille
  • Greg Gille
  • @unquotenews
  • 27 April 2015
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Biocartis, a Belgian molecular diagnostics company backed by several venture capital firms, has listed on the Euronext Brussels.

With a final offer price set at €11.50 per share, Biocartis reached a market cap of €450m (or €465m, assuming the full exercise of the over-allotment option). The offering solely comprised new shares, allowing the business to raise €100m prior to the exercise of the over-allotment option. Shares started trading on Euronext Brussels on 27 April.

KBC Securities acted as sole global coordinator in the offering. KBC Securities, Kempen & Co and Petercam acted as joint bookrunners.

Biocartis

  • DEAL:

    IPO

  • VALUE:

    €450m

  • LOCATION:

    Mechelen

  • SECTOR:

    Biotechnology

  • FOUNDED:

    2007

Existing Biocartis shareholders committed to subscribe for an overall €21.5m as part of the IPO.

Previous funding
The company has been the recipient of a number of funding rounds over the past few years. Biocartis's series-A round took place in October 2009 – Advent Venture Partners, Biovest, KBC Private Equity and Aescap Venture provided €10m to the company.

Biovest, Advent and Aescap committed a further €30m the following April, alongside Johnson & Johnson Development Corporation (JJDC) and Debiopharm in the company's series-B.

PMV then invested in the company in November 2011 as part of a €71m series-C round. The capital injection was provided by a large consortium comprising PMV, Debiopharm, Philips, Valiance, Biovest, Wellcome Trust, New Rhein Healthcare, several family offices and members of Biocartis's senior management team.

The company's series-D round took place in December 2012, with PMV providing €11m of the €34.5m funding round. The majority of the business's previous backers reinvested in the round. The company then raised €30m in its series-E round from a group of investors including PMV, Debiopharm Diagnostics and JJDC at the end of 2013.

Biocartis most recently raised €64.5m from its backers in September 2014.

Company
Founded in 2007, Biocartis develops diagnostics systems with the aim of providing point-of-need personalised diagnostics tests. Its diagnostics platforms are designed predominantly for molecular oncology applications. The company is headquartered in Mechelen, Belgium.

People
Rudi Pauwels is CEO and founder of Biocartis.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Exits
  • Healthcare
  • Benelux
  • Switzerland
  • IPO
  • Unq2015May

More on Exits

Public sector software
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • Exits
  • 04 September 2023
Lender taking the keys from a sponsor
Ares Management handed keys to two-thirds of UK sponsor’s portfolio

Lender provided GBP 500m for three of the GP's deals between 2016 and 2019, Debtwire reported

  • Financing
  • 30 August 2023
Luggage and airport services
Actera Group explores strategic options for Celebi Ground Handling

Several investors placed bids for the company in 2022 but mismatch in pricing didn't lead to a deal

  • Exits
  • 30 August 2023
HR software solutions providers
Main Capital’s Assessio to be sold to Pollen Street

Recruitment software company tripled in revenue under Main Capital’s ownership

  • Buyouts
  • 25 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013